Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves

被引：0
|
作者：
Obeng-Kusi, Mavis
Roe, Denise
Erstad, Brian L.
Abraham, Ivo
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Univ Arizona Canc Ctr, Tucson, AZ USA
[3] Univ Arizona Pharm, Dept Pharm Practice & Sci, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3605
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative efficacy of later-line therapies for metastatic colorectal cancer (mCRC) using novel methods for patient survival data reconstruction and network meta-analysis (NMA) of survival curves
    Abraham, Ivo
    Obeng-Kusi, Mavis
    Roe, Denise
    Erstad, Brian L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves
    Obeng-Kusi, Mavis
    Martin, Jennifer R.
    Roe, Denise
    Erstad, Brian L.
    Abraham, Ivo
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 923 - 932
  • [3] Cost-utility analyses of later-line treatments for metastatic colorectal cancer (mCRC) by network meta-analysis (NMA) approach: Conventional constant hazard ratio vs novel survival curves methodologies
    Obeng-Kusi, Mavis
    Erstad, Brian L.
    Roe, Denise
    Abraham, Ivo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer
    Cho, Sang
    Bekaii-Saab, Tanios S.
    Hocum, Brian Thomas
    Grossman, Jamie
    Appukkuttan, Sreevalsa
    Babajanyan, Svetlana
    Yang, Min
    Lee, Woojung
    Barzi, Afsaneh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
    Lakdawalla, D.
    Penrod, J.
    Maclean, R.
    Humphrey, J. S.
    Seabury, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
    Xue, Wen-Hui
    Li, Xue-Wei
    Ding, Ya-Qian
    Wu, Na
    Pei, Bei-Bei
    Ma, Xiao-Yan
    Xie, Jun
    Yang, Wen-Hui
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Targeted therapies for metastatic colorectal cancer (mCRC): A systematic review of cost-effectiveness (CE).
    Bentley, Tanya G.
    Broder, Michael Samuel
    Das, Lopamudra
    Ortendahl, Jesse
    Su, Yun
    Wagner, Samuel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [9] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [10] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345